• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在随机对照试验中衡量成本和经济效益。

Measuring costs and financial benefits in randomized controlled trials.

作者信息

Bulpitt C J, Fletcher A E

机构信息

Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, England.

出版信息

Am Heart J. 1990 Mar;119(3 Pt 2):766-70; discussion 770-1. doi: 10.1016/s0002-8703(05)80059-6.

DOI:10.1016/s0002-8703(05)80059-6
PMID:2106770
Abstract

Economic assessment can be incorporated into clinical trials to evaluate and compare the costs and benefits of different health care programs. In this article the three main types of evaluation are discussed: cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis. The measurement of direct and indirect costs is described and specific examples are quoted. Full economic analyses are given for the use of naftidrofuryl in the treatment of acute cerebral hemisphere infarction and the use of auranofin in the treatment of rheumatoid arthritis. Economic evaluation is seen to be justified whenever a more expensive treatment is expected to produce greater benefit. Such analyses should consider quality of life and health status, as well as the more easily identifiable outcomes.

摘要

经济评估可纳入临床试验,以评估和比较不同医疗保健方案的成本和效益。本文讨论了三种主要的评估类型:成本效益分析、成本效用分析和成本效益分析。描述了直接和间接成本的计量方法,并列举了具体实例。给出了萘呋胺酯治疗急性脑半球梗死和金诺芬治疗类风湿关节炎的完整经济分析。每当预期更昂贵的治疗会产生更大效益时,经济评估就被认为是合理的。此类分析应考虑生活质量和健康状况,以及更易于确定的结果。

相似文献

1
Measuring costs and financial benefits in randomized controlled trials.在随机对照试验中衡量成本和经济效益。
Am Heart J. 1990 Mar;119(3 Pt 2):766-70; discussion 770-1. doi: 10.1016/s0002-8703(05)80059-6.
2
Economic assessments in randomized controlled trials.随机对照试验中的经济评估。
Med J Aust. 1990 Aug 6;153(S1):S16-9. doi: 10.5694/j.1326-5377.1990.tb136984.x.
3
The cost effectiveness of auranofin: results of a randomized clinical trial.金诺芬的成本效益:一项随机临床试验的结果
J Rheumatol. 1988 Jan;15(1):35-42.
4
Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.德国类风湿关节炎序贯使用包括来氟米特在内的改善病情抗风湿药的成本效益和成本效用建模:II. 来氟米特对效率的贡献
Pharmacoeconomics. 2005;23(4):395-420. doi: 10.2165/00019053-200523040-00008.
5
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany.阿达木单抗治疗德国类风湿关节炎的成本效益
Z Rheumatol. 2016 Dec;75(10):1006-1015. doi: 10.1007/s00393-016-0071-9.
6
[Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].来氟米特对德国类风湿关节炎序贯性改善病情抗风湿药治疗成本效益的贡献
Z Rheumatol. 2004 Feb;63(1):59-75. doi: 10.1007/s00393-004-0570-y.
7
Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.英夫利昔单抗:对其在类风湿关节炎治疗中应用的药物经济学综述
Pharmacoeconomics. 2004;22(2):107-32. doi: 10.2165/00019053-200422020-00004.
8
Methods of assessing the effect of drug therapy on quality of life.
Drug Saf. 1990 Jul-Aug;5(4):233-42. doi: 10.2165/00002018-199005040-00001.
9
Economic evaluation of an intervention program with the aim to improve at-work productivity for workers with rheumatoid arthritis.一项旨在提高类风湿性关节炎患者工作效率的干预计划的经济评估。
J Occup Health. 2017 May 25;59(3):267-279. doi: 10.1539/joh.16-0082-OA. Epub 2017 Apr 5.
10
Quality of life in patients receiving auranofin therapy: confirmation of efficacy using nontraditional health status measures.接受金诺芬治疗患者的生活质量:使用非传统健康状况指标对疗效的确认
Scand J Rheumatol Suppl. 1986;63:29-35.

引用本文的文献

1
Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections.环丙沙星加甲硝唑与亚胺培南-西司他丁治疗腹腔内感染的成本效益
Pharmacoeconomics. 1999 Nov;16(5 Pt 2):551-61. doi: 10.2165/00019053-199916050-00011.
2
Optimising the economic efficiency of drug studies.优化药物研究的经济效率。
Pharmacoeconomics. 1992 Nov;2(5):371-87. doi: 10.2165/00019053-199202050-00005.